Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.70
-0.2000-2.53%
Post-market: 8.060.3600+4.68%16:31 EDT
Volume:4.05M
Turnover:31.18M
Market Cap:697.34M
PE:-3.19
High:8.02
Open:7.95
Low:7.52
Close:7.90
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:2.43
T/O Rate:5.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.95
PE(LYR):-2.55

Loading ...

Verastem Gains on Positive Ovarian Cancer Drug Results

Reuters
·
Yesterday

Verastem announces data from analysis of Phase 2 RAMP 201 trial

TIPRANKS
·
Yesterday

Verastem Oncology Says RAMP 201 Analysis Shows 18% ORR for Avutometinib-Defactinib in Triple Wild-Type Recurrent LGSOC

Reuters
·
Yesterday

Verastem Oncology Announces New Ramp 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at Igcs 2026

THOMSON REUTERS
·
Yesterday

Verastem - Avutometinib Plus Defactinib Achieves 18% Orr, 13 Months Median Pfs in Triple Wild-Type Lgsoc

THOMSON REUTERS
·
Yesterday

Verastem - Avutometinib Plus Defactinib Achieves 44% Orr, 94% Disease Control Rate in Japanese Lgsoc Study

THOMSON REUTERS
·
Yesterday

Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal

TIPRANKS
·
Sep 29

Verastem Reports 2-Year RAMP 201 Data for Avutometinib-Defactinib Combo in Recurrent Low-Grade Serous Ovarian Cancer

Reuters
·
Sep 29

Verastem Flags RAMP 201 Biomarker Data for Late-Breaking Oral Presentation at IGCS 2026

Reuters
·
Sep 24

GenFleet Hits over 3-Week High as Cancer Drug Makes Progress on BTD List

Reuters
·
Sep 23

GenFleet Schedules Oct. 15 Investor Call to Release Preliminary Gfh375-Cetuximab Trial Data in KRAS G12D Tumors

Reuters
·
Sep 23

Verastem (VSTM) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Sep 22

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

MT Newswires Live
·
Sep 18

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

TIPRANKS
·
Sep 18

Verastem Initiated at Outperform by Wolfe Research

Dow Jones
·
Sep 17

Wolfe Research Initiates Verastem at Outperform

MT Newswires Live
·
Sep 17

Verastem initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17

Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target

TIPRANKS
·
Sep 12

Verastem Price Target Maintained with a $18.00/Share by BTIG

Dow Jones
·
Sep 11

Verastem Sets Oct. 14 Investor Event to Present New Vs-7375 KRAS G12D Trial Data Across Solid Tumors

Reuters
·
Sep 08